CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach for combating cancers, demonstrating remarkable efficacy in relapsed/refractory hematological malignancies in both pediatric and adult patients. CAR-natural killer (CAR-NK) cell complements CAR-T cell therapy by offering several distinct advantages. CAR-NK cells do not require HLA compatibility and exhibit low safety concerns. Moreover, CAR-NK cells are conducive to "off-the-shelf" therapeutics, providing significant logistic advantages over CAR-T cells. Both CAR-T and CAR-NK cells have shown consistent and promising results in hematological malignancies. However, their efficacy against…

• UD
  U.S. Department of Defense

  Award: W81XWH-21-1-0514
• CR
  Cancer Research Institute

  Award: CRI4964
• PS
  Pershing Square Sohn Cancer Research Alliance
• NI
  National Institutes of Health

  Awards: W81XWH, R33CA281702
• CF
  Center for Information Technology

  Award: R33CA281702